Hai Nguyen
Cardiovascular Disease · Honolulu, HINPI 1821150905
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Baxter Healthcare at 39.1% of the total. Reporting peaked in 2020 at $1,704 and has fallen 86.9% since, to $222 in 2025.
Across 27 payments — averaging $137.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$1K
- Pfizer$524
- Abbott$473
- Medtronic$180
- Beone Medicines USA, Inc.$150
- La Jolla Pharmaceutical Company$136
- plus $802 from 10 others
What the payments were for
- Consulting fees$1,45539%
- Speaking & faculty fees$451%
- Food & beverage$2,22060%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 1 | $1,455 |
| Pfizer | 5 | $524 |
| Abbott | 3 | $473 |
| Medtronic(2 entities) | 2 | $180 |
| Beone Medicines USA, Inc. | 1 | $150 |
| La Jolla Pharmaceutical Company | 2 | $136 |
| Edwards Lifesciences | 1 | $133 |
| Portola Pharmaceuticals, LLC | 1 | $129 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Philips North America LLC | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 1 | $98 |
| Lantheus Medical Imaging, Inc. | 3 | $62 |
| BD | 1 | $45 |
| Exeltis, USA Inc. | 2 | $35 |
| Merck | 1 | $34 |
| Cvrx, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fluid Systems - Research Devel$1,455
- MitraClip$348
- VYNDAQEL$328
- TEVIMBRA$150
- CoreValve Evolut$136
- Edwards SAPIEN 3 Transcatheter Heart Valve$133
- GIAPREZA$131
- ANDEXXA$129
- CARDIOMEMS$125
- IQIRVO$125
- IGT_D Systems$113
How this compares
$3,720 in reported general payments places this provider in the 65th percentile of 73 cardiovascular disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 277 | $442,279 |
| PradaxaDabigatran Etexilate Mesylate | 323 | $89,733 |
| Repatha SureclickEvolocumab | 52 | $72,137 |
| EntrestoSacubitril/Valsartan | 64 | $70,464 |
| JardianceEmpagliflozin | 102 | $50,610 |
| Repatha SyringeEvolocumab | 23 | $27,847 |
| XareltoRivaroxaban | 18 | $25,498 |
| BrilintaTicagrelor | 24 | $23,460 |
| Praluent PenAlirocumab | 11 | $11,876 |
| Flecainide Acetate | 242 | $9,420 |
| Potassium Chloride | 163 | $6,280 |
| Metoprolol Tartrate | 521 | $5,378 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 29 | $5,180 |
| Metoprolol Succinate | 339 | $4,865 |
| Furosemide | 350 | $4,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $524 | $442,279277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 73 cardiovascular disease providers in Hawaii.
Other cardiovascular disease in Honolulu
- Dipanjan BanerjeeHonolulu$331K
- Joana MagnoHonolulu$23K
- Hingson ChunHonolulu$23K
- William DangHonolulu$16K
- Edward ShenHonolulu$12K
- Se Kon WonHonolulu$11K
- Wesley KaiHonolulu$10K
- Calvin WongHonolulu$8K
- Abdulelah NuqaliHonolulu$7K
- Mahdi Veillet-ChowdhuryHonolulu$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.